- Trial phase
- Approved (marketed); Phase 3 (APOLLO-B) completed
- Time to market
- Already approved and marketed, FDA approval recorded 2018-08-10; no new indication approval pending in local FDA records.
- Why 3/10
- No Onpattro-specific hard, dated catalyst exists in the next ~12 months, its FDA approval (2018-08-10) is long past and its Phase 3 APOLLO-B cardiomyopathy trial is completed with no pending regulatory decision on record, so as an approved legacy drug it is capped at 3-5 and scores 3 because it is a minor, shrinking part of a multi-program company (ALNY's recent FDA catalysts concern other drugs, e.g. the cemdisiran NDA filed 2026-04-30).
Do not position in ALNY for an ONPATTRO-specific catalyst, there isn't one on the horizon; treat ONPATTRO as a slowly amortizing cash-flow asset whose quarterly revenue lines (Q2 2026 10-Q filed 2026-07-30) are worth watching inside ALNY's earnings for the pace of patient transition to newer franchise drugs. ALNY's mean analyst target of ~$427.61 (observed 2026-07-31) implies the market values the pipeline, not this legacy product, so any trade thesis should hinge on the rest of the portfolio (e.g., cemdisiran) rather than ONPATTRO.
Price Chart
Executive Summary
ONPATTRO (patisiran) is Alnylam Pharmaceuticals' RNAi drug, whose FDA approval is recorded locally as an 2018-08-10 approval catalyst (the stock rose ~3.3% the day of that record, then gave back ~3.2% over five days). Its follow-on Phase 3 cardiomyopathy trial, APOLLO-B, has completed. As an already-approved, commercialized product with no pending regulatory decision, ONPATTRO is not a binary catalyst for ALNY; the stock's drivers today sit elsewhere in the pipeline.
How It Works
ONPATTRO is an RNA-interference (RNAi) medicine: a small engineered piece of genetic material that silences the liver gene making transthyretin, the protein that misfolds and forms damaging amyloid deposits in nerves and the heart. It is given as an intravenous infusion, whereas Alnylam's newer franchise drugs use a more convenient subcutaneous injection.
Trial Status
Phase 3 APOLLO-B (NCT03997383, 360 patients, ATTR amyloidosis with cardiomyopathy, sponsor Alnylam) is COMPLETED with results posted; primary completion was 2022-06-20 (actual) and the trial completion date is recorded as 2025-12-24. The original hATTR polyneuropathy approval (2018) is on record as an FDA approval catalyst.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for ONPATTRO itself in the next ~12 months.
- Company-level watch items: Q2 2026 earnings were released 2026-07-30 (10-Q/8-K filed), check commentary on ONPATTRO/ATTR franchise revenue; cemdisiran NDA (filed 2026-04-30 for generalized myasthenia gravis) has an as-yet-unrecorded FDA action date.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report